US approves new HIV drug

May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

Made by the New Jersey based Tibotec Therapeutics, Edurant helps block the virus from replicating and is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitor.

The pill is to be taken once daily with food, the FDA said.

"Patients may respond differently to various or experience varied side effects," said Edward Cox, director of the office of antimicrobial products in the FDA's Center for Drug Evaluation and Research.

"FDA's approval of Edurant provides an additional treatment option for patients who are starting ."

The approval followed phase II and II trials that showed that patients who had not received previous therapy saw an 83 percent lower viral load after they took Edurant along with other antiretroviral drugs.

Side effects included depression, insomnia, headache and rash.

Explore further: Linking the microbial and immune environment in semen to HIV viral load and transmission

add to favorites email to friend print save as pdf

Related Stories

FDA approves antiretroviral drug

Aug 07, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

Recommended for you

Lift U.S. ban on blood donations by gay men, experts say

4 hours ago

(HealthDay)—The United States should repeal a 30-year policy that bans blood donations from gay and bisexual men, according to a team of medical and legal experts writing this week in the Journal of th ...

How we got ahead in HIV control

7 hours ago

When AIDS first emerged in the early 1980s, HIV infection was a death sentence. But a global effort has ensured this is no longer the case for a growing number of people.

User comments : 0